Biopolym. Cell. 1998; 14(5):396-409.
Огляди
Чи мають місце антисенс-пептиди в теорії молекулярного впізнавання?
1Маркелова О. Ю., 1Швед А. Д.
- Інститут молекулярної біології і генетики НАН України
Вул. Академіка Заболотного, 150, Київ, Україна, 03680
Abstract
В огляді наведено результати досліджень взаємодії сенс-антисенс-пептидів, які свідчать, з одного боку, про високу афінність і специфічність зв'язування, з другого – про відсутність будь-якої взаємодії між ними. Експериментальні дані і теоретичні викладки різних авторів не дозволяють однозначно судити про те, чи мають місце антисенс-пептиди в теорії молекулярного впізнавання. Однак є впевненість у необхідності продовження пошукових робіт в обговорюваному напрямку.
Повний текст: (PDF, російською)
References
[1]
Brentani RR. Biological implications of complementary hydropathy of amino acids. J Theor Biol. 1988;135(4):495-9.
[2]
B?r? J. Comparative analysis of specificity in protein-protein interactions. Part II.: The complementary coding of some proteins as the possible source of specificity in protein-protein interactions. Med Hypotheses. 1981;7(8):981-93.
[3]
Mekler LB. [Specific selective interaction between amino acid groups of polypeptide chains]. Biofizika. 1969;14(4):581-4.
[4]
Mekler LB. ]On the origin of living cells: the evolution of biologically significant molecules transfer chemical evolution in the biological. A new approach to the problem]. Zh Vsesoyuz khim obshchestva im. D. I. Mendeleeva. 1980;25(4): 460-73.
[5]
Idlis RG. [The principle of cross-stereo complementarity and symmetry of the genetic code]. Zh Vsesoyuz khim obshchestva im. D. I. Mendeleeva. 1980; 25(4):431-4.
[6]
Blalock JE, Smith EM. Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem Biophys Res Commun. 1984;121(1):203-7.
[7]
Bost KL, Smith EM, Blalock JE. Regions of complementarity between the messenger RNAs for epidermal growth factor, transferrin, interleukin-2 and their respective receptors. Biochem Biophys Res Commun. 1985;128(3):1373-80.
[8]
Snell CR. A classification of peptide ligands based on their predicted receptor conformation. Biochim Biophys Acta. 1984;787(1):53-60.
[9]
Segerst?en U, Nordgren H, Biro JC. Frequent occurrence of short complementary sequences in nucleic acids. Biochem Biophys Res Commun. 1986;139(1):94-101.
[10]
Markus G, Tritsch GL, Parthasarathy R. A model for hydropathy-based peptide interactions. Arch Biochem Biophys. 1989;272(2):433-9.
[11]
Chipens GI. Structural basis of peptide and protein immunoregulators action . Riga Zinatne. 1990. 48 p.
[12]
Chipens GI, Ievina NG, Tsilinskis EE. [Hidden symmetry of peptide and protein primary structures]. Bioorg Khim. 1992;18(12):1445-53.
[13]
Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982;157(1):105-32.
[14]
Bost KL, Smith EM, Blalock JE. Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc Natl Acad Sci U S A. 1985;82(5):1372-5.
[15]
Clarke BL, Bost KL. A monoclonal anti-peptide antibody recognizes the adrenocorticotropic receptor. Biochem Biophys Res Commun. 1990;168(3):1020-6.
[16]
Mulchahey JJ, Neill JD, Dion LD, Bost KL, Blalock JE. Antibodies to the binding site of the receptor for luteinizing hormone-releasing hormone (LHRH): generation with a synthetic decapeptide encoded by an RNA complementary to LHRH mRNA. Proc Natl Acad Sci U S A. 1986;83(24):9714-8.
[17]
Shai Y, Flashner M, Chaiken IM. Anti-sense peptide recognition of sense peptides: direct quantitative characterization with the ribonuclease S-peptide system using analytical high-performance affinity chromatography. Biochemistry. 1987;26(3):669-75.
[18]
Brentani RR, Ribeiro SF, Potocnjak P, Pasqualini R, Lopes JD, Nakaie CR. Characterization of the cellular receptor for fibronectin through a hydropathic complementarity approach. Proc Natl Acad Sci U S A. 1988;85(2):364-7.
[19]
Pasqualini R, Chamone DF, Brentani RR. Determination of the putative binding site for fibronectin on platelet glycoprotein IIb-IIIa complex through a hydropathic complementarity approach. J Biol Chem. 1989;264(24):14566-70.
[20]
Elton TS, Dion LD, Bost KL, Oparil S, Blalock JE. Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci U S A. 1988;85(8):2518-22.
[21]
Holsworth DD, Kiely JS, Root-Bernstein RS, Overhiser RW. Antisense-designed peptides: a comparative study focusing on possible complements to angiotensin II. Pept Res. 1994;7(4):185-93.
[22]
Carr DJ, Bost KL, Blalock JE. An antibody to a peptide specified by an RNA that is complementary to gamma-endorphin mRNA recognizes an opiate receptor. J Neuroimmunol. 1986;12(4):329-37.
[23]
Carr DJ, DeCosta B, Jacobson AE, Bost KL, Rice KC, Blalock JE. Immunoaffinity-purified opiate receptor specifically binds the delta-class opiate receptor ligand, cis-(+)-3-methylfentanylisothiocyanate, SUPERFIT. FEBS Lett. 1987;224(2):272-6.
[24]
Moore GJ, Ganter RC, Franklin KJ. Angiotensin 'antipeptides': (-)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist. Biochem Biophys Res Commun. 1989;160(3):1387-91.
[25]
Fassina G, Zamai M, Brigham-Burke M, Chaiken IM. Recognition properties of antisense peptides to Arg8-vasopressin/bovine neurophysin II biosynthetic precursor sequences. Biochemistry. 1989;28(22):8811-8.
[26]
Lu FX, Aiyar N, Chaiken I. Affinity capture of [Arg8]vasopressin-receptor complex using immobilized antisense peptide. Proc Natl Acad Sci U S A. 1991;88(9):3642-6.
[27]
Scapol L, Rappuoli P, Viscomi GC. Purification of recombinant human interferon-beta by immobilized antisense peptides. J Chromatogr. 1992;600(2):235-42.
[28]
Bajpai A, Hooper KP, Ebner KE. Interactions of antisense peptides with ovine prolactin. Biochem Biophys Res Commun. 1991;180(3):1312-7.
[29]
Andersen TT, Ebner KE. Reaction of the histidines of prolactin with ethoxyformic anhydride. A binding site modification. J Biol Chem. 1979;254(21):10995-9.
[30]
Nestor JJ, Moffatt J.G, Chan HW. Patent 4493795 USA.
[31]
Strokovskaya LI, Kalinina NO, Kikhno IM, Solomko AP. The expression of recombinant human prolactin with use of the baculovirus vector on the basis of Malacosoma Neustria nuclear polyhedrosis virus. Dopovidi Nats Akad Nauk Ukrainy. 1997; (1):166-9.
[32]
Kohmoto K, Tsunasawa S, Sakiyama F. Complete amino acid sequence of mouse prolactin. Eur J Biochem. 1984;138(2):227-37.
[33]
Kinet S, Goffin V, Mainfroid V, Martial JA. Characterization of lactogen receptor-binding site 1 of human prolactin. J Biol Chem. 1996;271(24):14353-60.
[34]
Luck DN, Gout PW, Kelsay K, Atkinson T, Beer CT, Smith M. Recombinant methionyl bovine prolactin: loss of bioactivity after single amino acid deletions from putative helical regions. Mol Endocrinol. 1990;4(7):1011-6.
[35]
Fassina G, Roller PP, Olson AD, Thorgeirsson SS, Omichinski JG. Recognition properties of peptides hydropathically complementary to residues 356-375 of the c-raf protein. J Biol Chem. 1989;264(19):11252-7.
[36]
Soffer RL, Bandyopadhyay S, Rosenberg E, Hoeprich P, Teitelbaum A, Brunck T, Colby CB, Gloff C. Unexpected binding of an octapeptide to the angiotensin II receptor. Proc Natl Acad Sci U S A. 1987;84(24):9219-22.
[37]
Knutson VP. Insulin-binding peptide. Design and characterization. J Biol Chem. 1988;263(28):14146-51.
[38]
Ghiso J, Saball E, Leoni J, Rostagno A, Frangione B. Binding of cystatin C to C4: the importance of sense-antisense peptides in their interaction. Proc Natl Acad Sci U S A. 1990;87(4):1288-91.
[39]
Blalock JE. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotechnol. 1990;8(6):140-4.
[40]
Chaiken IM. Bioaffinity chromatography: synergy between interactive chromatography and molecular recognition for the separation and analysis of macromolecules. J Chromatogr. 1989;488(1):145-60.
[41]
Narayanan SR. Preparative affinity chromatography of proteins.J Chromatogr A. 1994;658(2):237–58.
[42]
Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988;85(15):5409-13.
[43]
Fassina G, Corti A, Cassani G. Affinity enhancement of complementary peptide recognition. Int J Pept Protein Res. 1992;39(6):549-56.
[44]
Misra PK, Haq W, Katti SB, Mathur KB, Raghubir R, Patnaik GK, Dhawan BN. Enkephalin antisense peptides: design, synthesis, and biological activity. Pharm Res. 1993;10(5):660-1.
[45]
Rasmussen UB, Hesch RD. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem Biophys Res Commun. 1987;149(3):930-8.
[46]
Guillemette G, Boulay G, Gagnon S, Bosse R, Escher E. The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action. Biochem J. 1989;261(1):309.
[47]
de Gasparo M, Whitebread S, Einsle K, Heusser C. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor? Biochem J. 1989;261(1):310-1.
[48]
Blalock JE, Elton TS, Oparil S. `Complementary peptides': a response. Biochem J. 1989; 261(1):311-2.
[49]
Stefani M, Bucciantini M, Taddei N, Mincione G, Manao G, Ramponi G. Antisense peptides to the 43-57 region of acylphosphatase and to the 46-60 region of two isoenzymes of a low-M(r) phosphotyrosine protein phosphatase do not interact with the corresponding proteins. Biotechnol Appl Biochem. 1994;20 ( Pt 2):241-9.
[50]
Eberle AN, Drozdz R, Baumann JB, Girard J. Receptor-specific antibodies by immunization with "antisense" peptides? Pept Res. 1989;2(3):213-20.
[51]
Jurzak M, Pavo I, Fahrenholz F. Lack of interaction of vasopressin with its antisense peptides: a functional and immunological study. J Recept Res. 1993;13(5):881-902.
[52]
Goldstein A, Brutlag DL. Is there a relationship between DNA sequences encoding peptide ligands and their receptors? Proc Natl Acad Sci U S A. 1989;86(1):42-5.
[53]
Zull JE, Smith SK. Is genetic code redundancy related to retention of structural information in both DNA strands? Trends Biochem Sci. 1990;15(7):257-61.
[54]
Zull JE, Taylor RC, Michaels GS, Rushforth NB. Nucleic acid sequences coding for internal antisense peptides: are there implications for protein folding and evolution? Nucleic Acids Res. 1994;22(16):3373-80.
[55]
Baranyi L, Campbell W, Ohshima K, Fujimoto S, Boros M, Okada H. The antisense homology box: a new motif within proteins that encodes biologically active peptides. Nat Med. 1995;1(9):894-901.
[56]
Tropsha A, Kizer JS, Chaiken IM. Making sense from antisense: a review of experimental data and developing ideas on sense--antisense peptide recognition. J Mol Recognit. 1992;5(2):43-54.
[57]
Baranyi L, Campbell W, Okada H. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides. J Immunol. 1996;157(10):4591-601.
[58]
Efimov VA, Buriakova AA, Fradkov AF, Chakhmakhcheva OG. [Biosynthesis of human calcitonin and mini-proinsulin in bacterial cells in the form of hybrid proteins with corresponding antisense peptides and a metal-binding peptide]. Bioorg Khim. 1996;22(7):503-9.
